

~4-fold increase in bacterial species detection in these stool samples after CRISPRclean treatment. Sequencing data downsampled to 20 million reads.

Disclosures. Keith Brown, n/a, Jumpcode Genomics (Board Member, Employee, Shareholder)

994. Comparison of Lactate, Procalcitonin and a Gene Signature Assay Alone or in Combination to Differentiate Sepsis from Non-infectious Systemic Inflammation in ICU Patients

Erkan Hassan, Pharm.D., FCCM¹; Roy Davis, M.D.^{>1}; Dayle Sampson, Ph.D.¹; Russell Miller, MARS/VENUS Study Investigators, M.D.²; ¹Immunexpress, Clarksville, Maryland; ²Intermountain Health cAre, Salt Lake City, Utah

Session: P-56. Microbial Pathogenesis

Background. Procalcitonin (PCT) and serum lactate (L) are measures of bacterial infection and tissue hypoxia, respectively, but also used to discern sepsis from infection negative systemic inflammation (INSI). However, improved tools are needed to enhance this differentiation. A previously validated gene signature assay (SeptiCyt RAPID) and its correlated score (SeptiScore (SS)) has been reported to effectively differentiate sepsis from INSI.

Objective. To compare early L, PCT and SS results (alone or in combination) in differentiating sepsis from INSI in adult intensive care unit (ICU) patients (Pt).


Methods. Data from a previously reported, prospective study (8 sites). Inclusion criteria: (i) ICU admission with ≥ 2 signs of systemic inflammatory response syndrome; (ii) Therapeutic antibiotic administration; (iii) external 3-physician clinical review classifying each Pt as sepsis or INSI with ≥ 2 reviewer agreement; (iv) L, PCT & SS values within 24 hrs of ICU admission; (v) Statistical Analysis; (iv) Area under the receiving operator curve (AUROC), 95% confidence intervals (CI) via generalized linear models for: (i) Each parameter alone (L, PCT, SS); (ii) Combinations (L + PCT, L + SS, PCT + SS, All 3); (iii) AUROC discriminated Sepsis from INSI model: (a) < 0.7 Sub-Optimal; (b) 0.7-0.8 Good; (c) > 0.8 Excellent. Comparisons conducted via paired t-test.

Results. 222 pts, sepsis=113; INSI=109 Similar demographics between groups (NS). Mean age (SD) = 57.9 (17.1) yrs; 58.1% male). Overall mechanically ventilated 60.8% and hospital mortality 17.1%. AUCROC (95% CI) in Table and Figure; AUCROC of L, PCT or SS alone or in combination

	L	PCT	SS	ALL
Alone	0.56 (0.48-0.64)	0.76 (0.70-0.83)	0.85* (0.80-0.90)	
L		0.76 (0.70-0.82)	0.85* (0.80-0.90)	
PCT			0.86* (0.81-0.91)	
ALL				0.86* (0.81-0.91)

* P<0.01 SCR vs L, PCT or combination

L, PCT, SS Comparison of Sepsis vs INSI



Conclusion. L is sub-optimal in discriminating sepsis from INSI. PCT with or without L was acceptable but not as robust as SS. SS alone or in any combination provided superior and significant discrimination between sepsis and INSI. Incorporation of SS into the clinical assessment process for suspected sepsis pts should be evaluated to determine the impact on early detection and Pt management.

Disclosures. Erkan Hassan, Pharm.D., FCCM, Immunexpress (Consultant) Roy Davis, M.D., Immunexpress (Consultant) Immunexpress (Consultant, Shareholder) Dayle Sampson, Ph.D., Immunexpress (Employee, Shareholder)

995. A Murine Model of Klebsiella pneumoniae Gastrointestinal Colonization with Parenteral Vancomycin Administration

Bettina Cheung, BS¹; Marine Lebrun-Corbin, BS, MS¹; Alan R. Hauser, MD PhD¹; ¹Northwestern University, Chicago, Illinois

Session: P-56. Microbial Pathogenesis

Background. As a leading cause of nosocomial infections, *Klebsiella pneumoniae* poses a significant threat due to its propensity to acquire resistance to many classes of antibiotics, including carbapenems. Gastrointestinal (GI) colonization by *K. pneumoniae* is a risk factor for subsequent infection as well as transmission to other patients. To study this crucial step in pathogenesis, we developed a mouse model of *K. pneumoniae* GI colonization using a clinically relevant parenteral antibiotic regimen.

Methods. To improve the clinical relevance of our model, we elected to use intraperitoneal injections of vancomycin, one of the most highly utilized antibiotics in the United States.

Results. To optimize dosage in C57bl/6 mice, we injected 20mg/kg, 350mg/kg, or vehicle (PBS) for three days prior to gastric gavage with 10⁸ colony forming units (CFU) of a low-resistance strain of *K. pneumoniae*. The mice who received 350mg/kg (a mouse equivalent of a human dose of 1g/day calculated through the FDA guidelines for estimating safe dosing) shed about 10⁷ CFU/g of feces at Day 7 while those receiving the lower dose or vehicle shed 10⁴ CFU/g. Next, we compared 3- or 5-day pre-treatments with vancomycin prior to inoculation with an ST258 (epidemic carbapenem-resistant) strain. At Day 7 post-inoculation, mice who received 5 days shed 10¹⁰ CFU/g feces while those who received vancomycin for 3 days or vehicle for 5 days (PBS) shed 10⁶ or 10⁴ CFU/g feces respectively. Thus, we chose 5 days of 350mg/kg vancomycin injection as our regimen for inducing robust GI colonization in mice. Finally, we tested the durability of colonization by following fecal shedding in mice up to Day 60 post-inoculation with a second ST258 strain. Shedding during the first 7 days occurs at about 10¹⁰ CFU/g feces, and from day 14 to day 60 fecal loads are stable around 10⁷ CFU/g feces. Results are comparable between male and female mice.

Conclusion. In conclusion, we have developed a mouse model of robust, prolonged GI colonization with multiple strains of *K. pneumoniae* using controlled dosing of a clinically relevant antibiotic. This model may be used to study a key step in *K. pneumoniae* pathogenesis and infection prevention in the future.

Disclosures. All Authors: No reported disclosures

996. CD4+ T-Cell Lymphopenia Associated with Frequent Plateletpheresis in Healthy Donors

Phoebe H. Cunningham, BA¹; Xhoi Mitre, BA²; Djenane Pierre, B.S.²; Christina Montesano, B.S.²; Tenaizus Woods, M.S.²; Karina Oganezova, BS²; Jonathan H. Krauss, n/a³; Salena S. Von, n/a²; John A. Kupelian, n/a⁴; Jon A. Gothing, RN MSN NP-C²; Kleinjan Jane, Masters²; Lise Ann Caldara, PA-C/MPAS⁵; Amy C. Sherman, MD⁶; Stephen R. Walsh, MDCM³; Richard M. Kaufman, MD²; Lindsey R. Baden, MD²; Michaël Desjardins, MD²; ¹Brigham & Women's Hospital, Brookline, Massachusetts; ²Brigham and Women's Hospital, Boston, Massachusetts; ³Brigham & Women's Hospital, Boston, Massachusetts; ⁴Brigham and Women's, Watertown, Massachusetts; ⁵Brigham & Womens Hospital, Boston, Massachusetts; ⁶Harvard Medical School/Brigham and Women's Hospital, Jamaica Plain, Massachusetts

Session: P-56. Microbial Pathogenesis

Background. Frequent plateletpheresis using the Time Accel leukoreduction system chamber may result in lymphopenia in healthy donors, with increased donation in the previous year associated with CD4+ T-cell count of less than 200 cells/μL. However, this finding has not been replicated and the clinical significance of plateletpheresis-associated lymphopenia remains unclear.

Methods. A prospective observational study of healthy plateletpheresis donors aged 18 or older who donated at least once in the previous 365 days was conducted at the Kraft Blood Center at Brigham and Women's Hospital/Dana Farber Cancer Institute, where the Time Accel system is used exclusively. Blood was drawn immediately before plateletpheresis or at least 2 weeks after the last donation to assess for total lymphocyte and CD4+ T-cell counts.

Results. A total of 86 participants were enrolled: 23 had 1-5 donations, 36 had 6-19 donations, and 27 had 20-24 donations within the previous 365 days (Figure 1). For the low-, medium-, and high-frequency donation groups, the median age was 53 years (IQR 43-64), 61 years (IQR 53-68), and 61 years (IQR 55-65), respectively. The median total lymphocyte count was 1.5 (IQR 1.3-1.9), 1.2 (IQR 0.9-1.5), 0.8 (IQR 0.6-0.9) 10³ cells/μL, and the median CD4+ T-cell count was 648 (IQR 531-843), 525 (IQR 348-698), and 220 (IQR 184-347) cells/μL. CD4+ T-cell counts were < 200 cells/μL in 0/23 (0%), 3/36 (8%), and 9/27 (33%) participants across the three groups. Total lymphocyte and CD4+ T-cell counts were inversely correlated with the number of platelet donations in the prior 365 days, R² = 0.384 (Fig 2) and 0.402 (Fig 3) respectively.




Figure 1. Distribution of platelet donations in prior 365 days.




Figure 2. Relationship between absolute lymphocyte count and platelet donations in prior 365 days.




Figure 3. Relationship between CD4+ T-cell count and platelet donations in prior 365 days.

Conclusion. Frequent plateletpheresis using Time Accel leukoreduction system chamber is associated with CD4+ T-cell lymphopenia, with counts below 200 cells/ μ L seen in one third of those who donated 20-24 times in the previous year. Vaccine immunogenicity studies are ongoing to evaluate the clinical significance of this finding.

Disclosures. Stephen R. Walsh, MDCM, Janssen Vaccines (Scientific Research Study Investigator) Regeneron (Scientific Research Study Investigator) Sanofi Pasteur (Scientific Research Study Investigator)

997. RLS-0071 Improves Survival in a Rat Model of Intestinal Necrosis

Kenji Cunnion, MD, MPH¹; Parvathi Kumar, MBBS¹; Brittany Lassiter, BS¹; Katherine LaValle, DVM²; Neel Krishna, PhD¹; ¹ReAlta Life Sciences, Norfolk, Virginia; ²ReAlta Life sciences, Norfolk, Virginia

Session: P-56. Microbial Pathogenesis


Background. Intestinal necrosis and perforation are potentially life-threatening medical conditions that can lead to bacterial sepsis and systemic inflammatory response syndrome. Various etiologies can compromise the intestinal wall causing leakage of luminal contents including enteric bacteria and precipitate aggressive immunological responses including the complement system and neutrophils. RLS-0071 is a peptide inhibitor of the classical and lectin pathways and known modulator of various neutrophil mediated effectors including myeloperoxidase activity and NETosis.

Methods. In this study we evaluated the extent to which immunomodulation via inhibition of the complement system and neutrophil effectors would alter survival in the setting of intestinal necrosis. Adolescent male Long-Evans rats were subject to cecal ligation and puncture (CLP) with one cohort receiving 40 mg/kg of RLS-0071 thirty minutes after surgery while the control group received no treatment. Survival of the rats was then assessed up to 5 days after surgery.

Results. Animals treated with RLS-0071 demonstrated nearly 1.5-fold increase in survival compared to the untreated group. In order to further elucidate the increase in survival we explored inflammatory responses as assessed by markers of NETosis i.e., free DNA in plasma, and the pro-inflammatory cytokine, IL-6. A reduction in blood levels of free DNA and the inflammatory cytokine IL-6 were observed for animals treated with RLS-0071.

RLS-0071 increases survival of rats after cecal ligation


Kaplan-Meier Survival Curve



Kaplan-Meier survival curve assessment. The red line indicates the outcome after 75% CLP in animals not receiving treatment (n=13), whereas red curves represent the outcome after animals received a single dose of 40 mg/kg RLS-0071 (n=11).

RLS-0071 reduces free DNA levels in the blood


Free DNA Levels 24hr Post-CLP (Single Dose RLS-0071)



Plasma was isolated before surgery (pre-bleed) (n=7) and from animals subject to CLP with (n=4) and without (n=3) RLS-0071 administration 24 hours post-surgery. Plasma samples were incubated with PicoGreen. Fluorescence was read at an excitation wavelength of 485 nm and an emission wavelength of 520nm in a microplate reader. Data are means and standard error of the means

RLS-0071 reduces IL-6 levels in the blood

IL-6 Plasma Levels 24hr Post-CLP (Single Dose RLS-0071)



Plasma was isolated before surgery (pre-bleed) (n=8) and from animals subject to CLP with (n=3) and without (n=5) RLS-0071 administration 24 hours post-surgery. Plasma samples were analyzed in an IL-6 ELISA according to the manufacturer's instructions. Data are means and standard error of the means.

Conclusion. The results of these experiments demonstrate that RLS-0071 can increase survival after intestinal perforation by multi-pronged modulation of complement activation, neutrophil immune mechanisms and cytokine mediated inflammatory responses.

Disclosures. Kenji Cunnion, MD, MPH, ReAlta Life Sciences Inc (Board Member, Employee, Shareholder) Parvathi Kumar, MBBS, ReAlta Life Sciences Inc (Employee) Brittany Lassiter, BS, ReAlta Life Sciences Inc (Employee) Katherine